EAU Podcast

When is urodynamic testing truly necessary, and when can it be avoided? How can clinicians make the right decision for each patient?In this episode, Prof. Enrico Finazzi Agrò (IT) is joined by Prof. Salvador Arlandis Guzmán (ES), Prof. Tufan Tarcan (TR) and Prof. Maurizio Serati (IT) to discuss the role of urodynamics in everyday urological practice.Through practical clinical scenarios, the experts explore when urodynamic investigations provide valuable information, when they may be unnecessary, and how test results can influence diagnosis and treatment decisions. The discussion highlights the importance of appropriate patient selection, understanding the limitations of testing, and balancing clinical guidelines with individual patient needs.This podcast is brought to you in collaboration with the EAU Section of Functional Urology.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

In this episode, UROONCO PCa associate editor Dr. Pawel Rajwa speaks with Prof. Matthew Cooperberg from the University of California about genomic and AI-based risk classifiers in localised prostate cancer and how these tools are helping to personalise patient care.They discuss how genomic and AI classifiers complement traditional risk assessment, including PSA levels, Gleason score, and MRI findings, and how advanced risk stratification tools can help identify suitable candidates for active surveillance and guide individualised treatment strategies.They look ahead at the future of genomics, artificial intelligence, and precision medicine in improving outcomes for men with prostate cancer.For more updates on prostate cancer, please visit our educational platform UROONCO PCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

How should female urinary mesh complications be assessed and managed, and what are the key considerations for treatment and long-term patient care?In this episode, Assoc. Prof. Tamsin Greenwell (GB) is joined by Dr. Eva Fong (NZ), Prof. Benoît Peyronnet (FR) and Dr. Tom Brits (BE) to discuss the management of mesh-related complications in female urology and the challenges they present in clinical practice.Their conversation explores the evolution of mesh use in pelvic floor surgery, the range of complications patients may experience, and the importance of thorough clinical assessment and multidisciplinary care.The faculty discuss different surgical approaches to mesh removal, the risks of persistent pain and recurrent incontinence, and the challenges of setting realistic treatment expectations. They also highlight the importance of shared decision-making, long-term follow-up and patient-reported outcomes, while reflecting on lessons learned regarding informed consent, patient safety and the responsible introduction of new surgical technologies.This podcast is brought to you in collaboration with the EAU Section of Genitourinary Reconstructive Surgeons.Further reading and resources:https://www.nice.org.uk/guidance/ng123/resources/treating-complications-from-mesh-used-for-stress-urinary-incontinence-options-for-women-referred-to-specialist-centres-patient-decision-aid-pdf-6725286117https://www.nice.org.uk/guidance/ng123/resources/treating-complications-from-mesh-used-for-pelvic-organ-prolapse-options-for-women-referred-to-specialist-centres-patient-decision-aid-pdf-6725286116https://bsug.org.uk/budcms/includes/kcfinder/upload/files/info-leaflets/BSUG-Obturator-V1.pdfhttps://bsug.org.uk/budcms/includes/kcfinder/upload/files/info-leaflets/BSUG-Retropubic-V1.pdfhttps://bsug.org.uk/budcms/includes/kcfinder/upload/files/info-leaflets/BSUG_Removal-of-Vaginal-mesh-for-prolapse.pdfhttps://bsug.org.uk/budcms/includes/kcfinder/upload/files/info-leaflets/BSUG_Removal-of-Abdominal-mesh-for-Pelvic-organ-prolapse-and-rectal-prolapse.pdfhttps://rdcu.be/wc4iBCYgwvjahttps://www.sciencedirect.com/special-issue/102LP96SPZCFor more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

In this episode, UROONCO BCa chief editor Dr. Benjamin Pradere interviews Assoc. Prof. Yige Bao about his ESMO26 presentation of the Phase II WUTSUP-02 trial results. The WUTSUP-02 trial (ChiCTR2300067836) is a prospective, multi-centre, phase II study evaluating perioperative tislelizumab plus disitamab vedotin for upper tract urothelial carcinoma (UTUC). They discuss the study design, patient population, and key trial endpoints, before reviewing the efficacy, survival, and safety results, including treatment-related adverse events. Their conversation also examines the clinical significance of these findings, their potential impact on the treatment landscape for UTUC, and the next steps needed to further evaluate HER2-targeted therapies and move toward broader clinical implementation.For more details on this study, you can read the abstract on the UROONCO BCa Educational Platform.This interview was recorded at ESMO26. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

In this episode, UROONCO BCa chief editor Dr. Benjamin Pradere interviews Assoc. Prof. Andrea Necchi about the results from the phase 3 CA017-078 (ENERGIZE) trial, which he presented at ESMO26. The trial investigates neoadjuvant chemotherapy alone versus in combination with nivolumab, followed by postsurgical adjuvant nivolumab, in patients with muscle-invasive bladder cancer (MIBC). Assoc. Prof. Andrea Necchi discusses the rationale and design of the trial, as well as the implications of its negative results, with neither co-primary endpoint, pathological complete response (pCR) and event-free survival (EFS) being met. They also talk about the potential role of circulating tumour DNA (ctDNA) in treatment monitoring, risk stratification, and future clinical trial design.For more details on this study, you can read the abstract on the UROONCO BCa Educational Platform.This interview was recorded at ESMO26. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

How can urology become more sustainable, and what practical steps can healthcare professionals take to reduce their environmental impact?In this episode, Dr. Benjamin Pradère (FR) Chair of the Go Green Working Group is joined by Dr. Sanne Jansen (NL) and Dr. Horst Emanuel Lagos-Beitz (MX) to introduce this new EAU Working Group endorsed by the YUO and discuss sustainability initiatives in urological practice.Their conversation explores practical projects from the Netherlands and Mexico, including reducing plastic waste, recycling medical materials and improving sustainability in the operating room. The faculty also discuss the challenges of implementing greener practices, the importance of education and collaboration, and how small changes can contribute to more sustainable urological care.This podcast is brought to you in collaboration with the EAU Go Green Working Group.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

UROONCO PCa associate editor Assoc. Prof. Pawel Rajwa speaks with Assoc. Prof. Arvin George from Johns Hopkins University (US) about the current state and future direction of focal therapy for prostate cancer.They discuss a wide range of topics, including the ideal candidates for focal therapy, how treatment success should be defined, and which technologies currently offer the greatest potential.The conversation also explores practical aspects of clinical care, such as how to communicate the potential benefits and limitations of focal therapy to patients, what could further improve treatment outcomes, and what advice can be offered to urologists looking to enter the field and begin offering focal therapy to their patients.For more updates on prostate cancer, please visit our educational platform UROONCO PCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

What does it take to move from Latin America to the UK and build a career in a new healthcare system?In this second episode of the Beyond borders: Latin American voices in European urology series, Dr. Alejandra Bravo-Balado (ES) is joined by Dr. Florencia Frascheri (GB), a urologist from Argentina currently working in the UK. They discuss her journey from Argentina to the UK, including the practical steps involved in pursuing a fellowship, adapting to a different healthcare system and working in a new language.The conversation also explores the importance of mentorship, opportunities for research and professional development, and the work–life balance she has found in the UK. Dr. Frascheri also reflects on the personal side of building a life away from home and shares practical advice for young urologists considering a similar path.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

What does it take to leave an established career behind and build a new professional life as a urologist in Europe?In this first episode of the Beyond borders: Latin American voices in European urology series, Dr. Alejandra Bravo-Balado (ES) is joined by Dr. Mariela Corrales Acosta (FR), a urologist from Peru currently working in France. They discuss her journey from Latin America to Europe, including the challenges of validating her qualifications, adapting to a new healthcare system and culture, and establishing herself professionally abroad.The conversation also explores the importance of mentorship and resilience, differences in work–life balance, and the personal sacrifices that come with international mobility.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

In this episode, UROONCO PCa associate editor Prof. Claudia Kesch interviews Dr. Neeraj Agarwal, from Dana-Farber Cancer Institute on the recent results of the TALAPRO-3 trial. This trial investigates the efficacy and safety of TALA + ENZA in men with mCSPC bearing HRR gene alterations.Dr. Agarwal elaborates on the rationale of this trial and the key results. They also discuss the control arm in more detail, heterogeneity and HRR alteration, plus clinical practice of managing anaemia and treatment strategy in mHSPC. To know more on this trial, read the abstract. For more updates on prostate cancer, please visit our educational platform UROONCO PCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.